Using Robotic Automation to Enhance Standardization and Traceability in Clinical Diagnostics
June 6th 2023At ASMS 2023, Tabitha Hambidge of LGC presented a novel method for automating the certification of reference materials with the help of double exact matching isotope dilution mass spectrometry (DEM-IDMS).
LC–MS Methods Evaluate PFAS and Lipidomic Changes of Lettuce and Peanuts in Contaminated Soil
June 6th 2023In a talk at ASMS 2023, Rebecca L. Beres of the University of North Carolina at Chapel Hill focused on two types of analysis methods: liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) and a liquid chromatography, ion mobility spectrometry, and mass spectrometry (LC–IMS-MS) platform.
ASMS 2023 Will Host its Closing Event at the Houston Museum of Natural Science
May 26th 2023ASMS will conclude its conference at the Houston Museum of Natural Science (HMNS) on Thursday June 8th, from 7:00 to 10:00 pm. The HMNS is known for their paleontology display, giving attendees the opportunity to embark on a one-of-a-kind prehistoric journey while socializing with friends and colleagues.
An Interview with AI About Its Potential Role in Separation Science
May 17th 2023We interviewed an AI program (ChatGPT) for LCGC North America asking questions about AI and its role in various applications for separation science to include data analysis, and high performance liquid chromatography (HPLC), hydrophilic-interaction chromatography (HILIC), reversed-phase liquid chromatography (RPLC), liquid chromatography–mass spectrometry (LC–MS), gas chromatography–mass spectrometry (GC–MS), high resolution mass spectrometry (HRIM–MS), high resolution tandem mass spectrometry (HRMS/MS), and related topics.
New Analytical Tool Helps Probe Higher-Order Structure of Bispecific Antibody Therapeutics
April 24th 2023The development of a new tool that combines native ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) could lead to a better understanding of bsAbs and aid in the development of effective treatments for diseases that remain challenging for conventional mAb therapeutics to access.